• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

fair and balanced my ass













In onc and hem? Absolutely! These patients are facing life and death issues and the drugs are all hard on normal cells. There is no way to be ethical without discussion the whole picture and no way to do what is right for patients. You can't cover every detail of the PI and every rare or possible side effect but you aren't doing your job if you don't cover the primary ones.
 




Fanapt? Definitely not as to Ortho hypotension. Even initial sales piece mis represented alpha receptor affinity by factor of ten. Alpha receptor activity is responsible for hypotension.